Last reviewed · How we verify

Doxil and Vinorelbine

Hematology Oncology Consultants · Phase 2 active Small molecule

Doxil and Vinorelbine is a Vinca alkaloid and microtubule inhibitor Small molecule drug developed by Hematology Oncology Consultants. It is currently in Phase 2 development for Breast cancer, Lung cancer.

Docetaxel, a microtubule inhibitor, binds to tubulin and prevents microtubule assembly, thereby inhibiting cell division.

Docetaxel, a microtubule inhibitor, binds to tubulin and prevents microtubule assembly, thereby inhibiting cell division. Used for Breast cancer, Lung cancer.

At a glance

Generic nameDoxil and Vinorelbine
SponsorHematology Oncology Consultants
Drug classVinca alkaloid and microtubule inhibitor
TargetTubulin
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

This leads to cell cycle arrest at the G2/M phase and ultimately apoptosis. Vinorelbine, a vinca alkaloid, binds to tubulin and prevents microtubule polymerization, also inhibiting cell division.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Doxil and Vinorelbine

What is Doxil and Vinorelbine?

Doxil and Vinorelbine is a Vinca alkaloid and microtubule inhibitor drug developed by Hematology Oncology Consultants, indicated for Breast cancer, Lung cancer.

How does Doxil and Vinorelbine work?

Docetaxel, a microtubule inhibitor, binds to tubulin and prevents microtubule assembly, thereby inhibiting cell division.

What is Doxil and Vinorelbine used for?

Doxil and Vinorelbine is indicated for Breast cancer, Lung cancer.

Who makes Doxil and Vinorelbine?

Doxil and Vinorelbine is developed by Hematology Oncology Consultants (see full Hematology Oncology Consultants pipeline at /company/hematology-oncology-consultants).

What drug class is Doxil and Vinorelbine in?

Doxil and Vinorelbine belongs to the Vinca alkaloid and microtubule inhibitor class. See all Vinca alkaloid and microtubule inhibitor drugs at /class/vinca-alkaloid-and-microtubule-inhibitor.

What development phase is Doxil and Vinorelbine in?

Doxil and Vinorelbine is in Phase 2.

What are the side effects of Doxil and Vinorelbine?

Common side effects of Doxil and Vinorelbine include Neutropenia, Anemia, Thrombocytopenia.

What does Doxil and Vinorelbine target?

Doxil and Vinorelbine targets Tubulin and is a Vinca alkaloid and microtubule inhibitor.

Related